Close Menu

Qiagen

The NeuMoDx SARS-CoV-2 Test Strip can run on the firm's fully-automated mid- or high-throughput instruments.

The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.

Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.

The company plans to use the net proceeds to pay in part for its anticipated acquisition of Qiagen, as well as for general corporate purposes.

News items for the in vitro diagnostics industry for the week of March 16, 2020.

The QiaStat-Dx Respiratory SARS-CoV-2 Panel can detect and differentiate SARS-CoV-2 and 21 other respiratory pathogens in symptomatic patients.

The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.

According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.

The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.

Directing lab-developed tests through the emergency use authorization process has brought to light reagent supply shortages and other hurdles.

Pages